Interdisciplinary Safety Evaluation for Learning and Decision-Making.

Area of Science:

• Pharmacovigilance and Drug Safety
• Regulatory Science
• Clinical Trial Management

Background:

• The FDA's Investigational New Drug (IND) safety reporting Final Rule (21 CFR 312.32) mandates reporting of serious unexpected suspected adverse reactions (SUSARs).
• Identifying drug-related risks for events anticipated in the general patient population requires specific assessment strategies beyond individual case reviews.

Purpose of the Study:

• To provide guidance on assessing and reporting serious adverse events under IND safety reporting rules.
• To outline methods for sponsors to evaluate aggregate safety data for potential drug-induced risks.

Main Methods:

• Review of FDA IND safety reporting regulations and guidance.
• Discussion of aggregate data assessment strategies for anticipating and identifying potential drug-related adverse events.
• Consideration of factors such as event frequency differences, preclinical data, dose-response, mechanism of action, and class effects.

Main Results:

• Established approaches for evaluating serious adverse events not easily attributable to individual occurrences.
• Highlighted the importance of periodic aggregate data review by sponsors to assess potential drug causality.
• Provided examples demonstrating flexibility in meeting the spirit of the Final Rule through thoughtful processes.

Conclusions:

• A systematic and thoughtful process is crucial for identifying clinically important safety imbalances in aggregate data.
• Sponsors must apply sound clinical and quantitative judgment to maintain trial integrity while fulfilling safety reporting obligations.
• Flexible approaches combining various methods can effectively meet the requirements of IND safety reporting.